CMS Assigns Permanent J-Code to Apellis' SYFOVRE for Age-Related Macular Degeneration
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been assigned a permanent and product-specific J-code (J2781) for SYFOVRE, a treatment for geographic atrophy secondary to age-related macular degeneration, by the U.S. Centers for Medicare & Medicaid Services (CMS). The J-code will become effective on October 1, 2023.
September 25, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The assignment of a permanent J-code for Apellis' SYFOVRE by CMS is a positive development for the company. It could potentially increase the accessibility and usage of the treatment, thereby potentially boosting the company's revenues.
The assignment of a permanent J-code by CMS is a significant regulatory milestone for Apellis. It means that the treatment is recognized and can be billed under Medicare and Medicaid, potentially increasing its accessibility and usage. This could lead to increased revenues for Apellis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100